Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on mast cell therapeutics, with briquilimab as its core asset. The company is working to develop and commercialize treatments for chronic urticaria and other mast-cell-related indications, while also retaining rights to use briquilimab in stem cell clearance prior to hematopoietic stem cell transplantation.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBriquilimab, the company's main monoclonal antibody program, developed for mast cell-related diseases.
Research, preclinical work, and clinical trials supporting briquilimab and related indications.
Exclusive rights licensed from Amgen and Stanford University for specific uses of briquilimab.
Asiakkaat
Jasper does not yet sell commercial products; its near-term 'customers' are clinical trial participants, investigators, regulators, and future payers that will determine whether briquilimab can be approved and reimbursed. If approved, the company expects to commercialize in North America directly and may use partners outside North America, so future buyers would include physicians, hospitals, and specialty payers in the relevant disease areas.
Patients enrolled in briquilimab studies, especially chronic urticaria, to generate efficacy and safety data.
FDA and foreign agencies that review clinical packages and determine whether the drug can be approved.
Allergists, immunologists, and transplant-related clinicians who would prescribe briquilimab if approved.
Commercial and government payers that will decide coverage and reimbursement for launch.
Strategia
The company has narrowed its focus to briquilimab and chronic urticaria after halting enrollment in its asthma study and stopping other clinical and preclinical programs. Its strategy is to conserve capital, advance the most promising indication, and preserve optionality through licensing and strategic alliances while it seeks additional financing. Jasper also intends to broaden its pipeline over time with additional mast-cell indications and next-generation products if resources allow.
This is the company's highest-priority asset and the main path to value creation and eventual revenue.
The company expects continued losses and needs external funding to keep development programs running.
If approved, Jasper will need sales, marketing, manufacturing, and distribution capabilities to launch briquilimab.
Maantiede
Jasper is headquartered in the United States and currently operates as a development-stage biotech with no commercial sales infrastructure. Management has said it may build commercialization capabilities in North America first, while outside North America it may rely on licensing, co-sale, or co-promotion partners. That makes the U.S. the key operating base and North America the likely initial launch region if briquilimab is approved.
Riskit
Jasper is a pre-revenue biotech with significant accumulated losses, negative operating cash flow, and a continuing need for external capital. Its value depends heavily on clinical success, regulatory approval, and eventual reimbursement for briquilimab, while any setback in development, manufacturing, or funding could materially impair the business. The company also faces typical biotech risks around trial design, patient enrollment, IP protection, and changing FDA expectations.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Briquilimab must show adequate safety and efficacy in trials before approval and commercialization are possible.
Kohdistuu: Core asset and primary value driver
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company expects continued losses and may need to curtail programs if capital is unavailable.
Kohdistuu: Corporate runway and program continuity
- Regulatory riskVaikutus: KorkeaTodennäköisyys: Korkea
FDA requirements may change or additional studies may be required, delaying approval.
Kohdistuu: Approval timeline and development cost
- IP and licensing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business relies on exclusive licenses for briquilimab rights and must maintain those agreements.
Kohdistuu: Core product rights
- Commercialization and reimbursement riskVaikutus: KorkeaTodennäköisyys: Matala
Even with approval, the company must secure pricing and payer coverage to generate meaningful sales.
Kohdistuu: Launch adoption and revenue realization
Kirjanpito
Harkinnanvaraiset erätClinical trial, CRO, and manufacturing costs are often estimated before invoices are final.
Vaikutus: Can shift quarterly operating expense and liabilities
The company uses equity awards to attract and retain personnel in a competitive biotech labor market.
Vaikutus: Raises non-cash operating expense and affects loss metrics
The company noted accounting for warrants issued in connection with a 2025 offering.
Vaikutus: Can create volatility in other income/expense and equity
Halting programs can require assessment of whether related assets or rights remain recoverable.
Vaikutus: May cause one-time charges if projects are abandoned
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Tempest Therapeutics, Inc.
TPST · Pharmaceutical Preparations
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
OS Therapies Inc
OSTX · Pharmaceutical Preparations
OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates.
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Päivitetty: 24.9.2026